Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | UTS2R | Q9UKP6 | 7/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.50 |
| ▸ | GAA | P10253 | 2/20 | 0.50 |
| ▸ | MEN1 | O00255 | 2/20 | 0.50 |
| ▸ | POLB | P06746 | 2/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.50 |
| ▸ | NPC1 | O15118 | 3/20 | 0.47 |
| ▸ | RAB9A | P51151 | 2/20 | 0.47 |
| ▸ | ATM | Q13315 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6741282 | 0.95 | UTS2R (0.58) | UTS2RKMT2AGAAMEN1POLB | |
| SCHEMBL6609118 | 0.91 | UTS2R (0.65) | UTS2RKMT2AGAAMEN1POLB | |
| SCHEMBL6741634 | 0.87 | UTS2R (0.48) | UTS2RKMT2AGAAMEN1SMN1; SMN2 | |
| SCHEMBL6744784 | 0.85 | UTS2R (0.70) | UTS2RCACNA1B | |
| SCHEMBL6742628 | 0.85 | UTS2R (0.70) | UTS2RCACNA1B | |
| SCHEMBL6741197 | 0.84 | UTS2R (0.52) | UTS2RPOLBSMN1; SMN2NPC1RAB9A | |
| SCHEMBL6608407 | 0.82 | UTS2R (0.64) | UTS2RPOLBNPC1 | |
| SCHEMBL6839473 | 0.81 | UTS2R (0.45) | UTS2RKMT2AGAAMEN1POLB | |
| SCHEMBL6741883 | 0.81 | UTS2R (0.53) | UTS2RKMT2AMEN1SMN1; SMN2LMNA | |
| SCHEMBL6744737 | 0.81 | UTS2R (0.53) | UTS2RKMT2AMEN1SMN1; SMN2LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040152692-A1 | Urotensin antagonist; therapy for congestive heart failure; antiischemic agents; cardiovascular disorders; strokes; hypotensive agents; respiratory system disorders; restenosis; antiinflammatory agents; psychological disorders | SMITHKLINE BEECHAM CORPORATION | 2004-08-05 | — | — | US | claimed |
| EP-1379503-A1 | PYRROLIDINE SULFONAMIDES | SmithKline Beecham Corporation (US) | 2004-01-14 | — | — | EP | claimed |
| WO-2002079155-A1 | PYRROLIDINE SULFONAMIDES | SMITHKLINE BEECHAM CORPORATION (US) | 2002-10-10 | — | — | WO | claimed |
| US-20040152692-A1 | Urotensin antagonist; therapy for congestive heart failure; antiischemic agents; cardiovascular disorders; strokes; hypotensive agents; respiratory system disorders; restenosis; antiinflammatory agents; psychological disorders | SMITHKLINE BEECHAM CORPORATION | 2004-08-05 | — | — | US | disclosed |
| EP-1379503-A1 | PYRROLIDINE SULFONAMIDES | SmithKline Beecham Corporation (US) | 2004-01-14 | — | — | EP | disclosed |
| WO-2002079155-A1 | PYRROLIDINE SULFONAMIDES | SMITHKLINE BEECHAM CORPORATION (US) | 2002-10-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040152692-A1 | Urotensin antagonist; therapy for congestive heart failure; antiischemic agents; cardiovascular disorders; strokes; hypotensive agents; respiratory system disorders; restenosis; antiinflammatory agents; psychological disorders | UTS2R, PLAUR, SERPINE1 | UTS2R 1/4885KMT2A 4496/4885GAA 2350/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.